![Prostate cancer-specific mortality burden by risk group among men with localized disease](https://oncodaily.com/pub/uploads/2024/08/Edward-Christopher-Dee-Michelle-D.-Nezolosky-Fallon-E.-Chipidza-Melaku-A.-Arega-Santino-S.-Butler-Sybil-T.-Sha-Brandon-A.-Mahal-Paul-L.-Nguyen-David-D.-Yang-and-Vinayak-Muralidhar-e1722947542805.webp)
Prostate cancer-specific mortality burden by risk group among men with localized disease
Advanced Prostate Cancer Consensus Conference shared on X:
“Study aimed to assess the relative burden of Prostate Cancer specific mortality (PCSM) across different risk groups of N0M0 prostate cancer, using data from the 2004-2015 Surveillance, Epidemiology, and End Results database.
The analysis categorized patients into low, favorable intermediate, unfavorable intermediate, high, and very high-risk groups and calculated the 10-year PCSM for each group using the Fine-Gray method.
- Among the 337,162 men analyzed, high-risk and very high-risk groups accounted for only 21.1% of diagnoses but contributed to two-thirds of the deaths within ten years.
- The study also found that older patients and black patients, despite lower-risk profiles, had disproportionately higher mortality rates
These results highlight the need for focused research on high-risk prostate cancer and emphasize the importance of including older and black men in clinical trials to improve outcomes in these populations.”
Authors: Edward Christopher Dee, Michelle D. Nezolosky, Fallon E. Chipidza, Melaku A. Arega, Santino S. Butler, Sybil T. Sha, Brandon A. Mahal, Paul L. Nguyen, David D. Yang and Vinayak Muralidhar.